Deals, pipeline readouts and company news from across biotech and pharma.
UCB will use Cradle's AI-driven protein engineering platform in selected discovery projects, from hit generation to preclinical readiness, with no financial terms disclosed.
The US life-sciences supplier reported third-quarter revenue of $45.9 million, with TriLink mRNA products up 28%, and raised its full-year revenue and Adjusted EBITDA outlook.
Clinical Diagnostics growth offset a decline in Life Science, while a fair-value change on the Sartorius holding drove GAAP net income of $458.6 million; full-year guidance is unchanged.
The EVO ICL maker reports lower year-on-year net sales for the quarter ended 2 October 2026 and flags label expansions and upcoming presbyopia trials.
The packaging group reported 7% higher quarterly sales of $6.13bn but lowered its adjusted EPS guidance, citing the timing of cost pass-through.
The tobacco leaf and ingredients supplier reported net income of $12.6m, with delayed customer commitments cutting tobacco volumes by about 23%.
The animal health and nutrition company reports an 11% rise in net income to $29.5m, with its guidance still assuming no virginiamycin sales in Brazil.
OPKO Health agreed to sell its remaining BioReference diagnostic operations to Labcorp and reported third-quarter 2026 continuing-operations revenue of $65.4 million.
The US drug distributor also extended its CVS Health partnership to 2032, agreed to buy about 49% of Option Care Health and closed its Precision Medicine Group deal.
The heart-valve maker cites TAVR and TMTT growth, several recent FDA and European approvals, and CMS's final updated TAVR coverage determination.
The company posted a $190.1M third-quarter net loss and says it will file for aficamten in non-obstructive HCM in the US this quarter and in the EU in early 2027.
The bioelectronic medicine company narrowed its quarterly loss to $1.3 million and has asked the FDA to clear Quell for chronic chemotherapy-induced peripheral neuropathy.
The computational drug discovery company reported a $37.7m quarterly net loss and noted FDA Priority Review for Takeda's zasocitinib NDA in plaque psoriasis.
The US biotech posted $45.0m in third-quarter revenue, while FDA approved a label update for its ROS1+ lung cancer drug four months ahead of schedule.
Acadia Pharmaceuticals reported Q3 2026 revenue of $342 million and said DAYBUE (trofinetide) for Rett syndrome has launched in Germany after European Commission approval in August.
The US plasma company reported 31% year-on-year ASCENIV sales growth and kept its full-year revenue guidance, while the FDA responded positively to its pre-IND package for a pneumococcal candidate.
The aesthetics company posted an adjusted EBITDA profit despite a GAAP operating loss, and expects FDA approval of Evolysse Sculpt by the end of the year.
The precision oncology company says Phase 3 breast cancer enrollment should finish in mid-2027, with updated vascular anomaly data due at ASH on 14 December.
Arcutis raised its full-year sales outlook to $535–545 million, and the FDA has set a February 2027 action date for Zoryve cream in infants with atopic dermatitis.
The clinical-stage immune disease biotech says the share consolidation, aimed at regaining Nasdaq bid-price compliance, will cut shares outstanding from about 33.3 million to about 1.11 million.
The company kept its 2026 WAKIX revenue guidance at $1.00B-$1.04B and reported favourable 14-day Phase 1 multiple-ascending-dose data for its orexin-2 agonist BP-205.
Neuronetics narrowed its third-quarter net loss to $1.6M, holding full-year revenue guidance while an FDA 510(k) for an accelerated NeuroStar protocol is under review.
The royalty investor reported third-quarter Portfolio Receipts of $890m, lifted its full-year outlook and bought royalties on two newly commercial dermatology and rare-disease products for $100m each.
The US maker of the NeuroStar TMS system cites revenue and patient figures in an investor presentation that also flags going-concern and credit facility risks.
The preclinical contract research group reported Q3 revenue of $982.7 million, down 2.2% as reported after divestitures, and raised its full-year revenue and non-GAAP earnings outlook.
The wholesaler's full-year sales rose 5.0%, helped by the OneOncology acquisition, while it guides fiscal 2027 adjusted diluted EPS to $19.40-$19.75.
The US healthcare group lifted full-year profit and cash-flow forecasts, citing stronger performance in its insurance and pharmacy divisions, and flagged expanded GLP-1 weight management offerings.
The orthopaedic device maker reported hip and technology-segment growth, a drop in knees, and raised its 2026 organic growth and adjusted earnings guidance.
The US medical supplies group reported third-quarter net income of $318 million, helped by tariff refunds, and lifted its full-year organic sales growth guidance while holding its EBITDA outlook.
Geron reported a 5% quarterly rise in Rytelo sales and a small profit, lowered its 2026 operating expense guidance and discontinued its Phase 3 IMpactMF myelofibrosis trial.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.